organization · Reporting owner

Longitude Venture Partners IV, L.P.

Disclosed activity across 3 companies

Tapewire entity: 108418
SEC CIK: 0001787456

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Lexeo Therapeutics, Inc.LXEO · Entity 5687	10% owner	November 07, 2023	November 10, 2023
Vera Therapeutics, Inc.VERA · Entity 4358	10% owner	February 06, 2023	February 08, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Lexeo Therapeutics, Inc.

Report date November 07, 2023 · Filed November 10, 2023

Jointly reported with Longitude Capital Partners IV, LLC, Tammenoms Bakker Juliet, ENRIGHT PATRICK G

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Longitude Venture Partners IV, L.P.	2,567,100	Last balance in matching sequence After 2023-11-07 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2023-11-07 · Conversion · Acquired 1,793,429 · Balance 1,793,429 F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Row 2 · 2023-11-07 · Conversion · Acquired 319,126 · Balance 2,112,555 F3: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Row 3 · 2023-11-07 · Purchase · Acquired 454,545 · Balance 2,567,100 F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series A convertible preferred stockSEC Table II · derivative / convertible security	IndirectBy Longitude Venture Partners IV, L.P.	0	Reported balance After 2023-11-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-11-07 · Conversion · Disposed 18,999,999 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Series B convertible preferred stockSEC Table II · derivative / convertible security	IndirectBy Longitude Venture Partners IV, L.P.	0	Reported balance After 2023-11-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-11-07 · Conversion · Disposed 2,906,148 · Balance 0 F3: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

Vera Therapeutics, Inc.

Report date February 06, 2023 · Filed February 08, 2023

Jointly reported with Longitude Capital Partners IV, LLC, Longitude Prime Partners, LLC, Longitude Prime Fund, L.P., Tammenoms Bakker Juliet

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,714,285	Reported balance After 2023-02-06 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2023-02-06 · Purchase · Acquired 1,714,285 · Balance 1,714,285 F1: These shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	3,429,927	Reported balance Holding disclosure · report date 2023-02-06 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,429,927 F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Eargo, Inc.

Report date April 14, 2021 · Filed April 16, 2021

Jointly reported with Longitude Capital Partners IV, LLC, ENRIGHT PATRICK G

Section 16 reporting ended · disclosed 2021-04-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,918,691	Reported balance After 2021-04-14 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-04-14 · Other · Disposed 1,000,000 · Balance 2,918,691 F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners IV, L.P. ("LVP4") to its general and limited partners, pursuant to a Rule 10b5-1 trading plan. F2: These shares are held directly by LVP4. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of LVP4 and may be deemed to have voting, investment and dispositive power over the shares held by LVP4. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVP4. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by LVP4 and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. F3: (Continued from footnote 2) Juliet Tammenoms Bakker, a managing member of LCP4, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	5,012	Reported balance After 2021-04-14 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-04-14 · Other · Acquired 5,012 · Balance 5,012 F4: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP4 to its members. F5: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners IV, L.P. ("LVP4") to its general and limited partners, pursuant to a Rule 10b5-1 trading plan.

F2: These shares are held directly by LVP4. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of LVP4 and may be deemed to have voting, investment and dispositive power over the shares held by LVP4. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVP4. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by LVP4 and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3: (Continued from footnote 2) Juliet Tammenoms Bakker, a managing member of LCP4, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer.

F4: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP4 to its members.

F5: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 07, 2023 Filed Nov 10, 2023 01:32 UTC	Lexeo Therapeutics, Inc. LXEO · Entity 5687	ConversionSeries B convertible preferred stock · Derivative	2,906,148	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-054904 · doc4.xml · derivative · entry 5 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Longitude Venture Partners IV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 319,126 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. F3 · price: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. F3 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. F3 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
November 07, 2023 Filed Nov 10, 2023 01:32 UTC	Lexeo Therapeutics, Inc. LXEO · Entity 5687	ConversionSeries A convertible preferred stock · Derivative	18,999,999	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-054904 · doc4.xml · derivative · entry 4 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Longitude Venture Partners IV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,793,429 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
November 07, 2023 Filed Nov 10, 2023 01:32 UTC	Lexeo Therapeutics, Inc. LXEO · Entity 5687	PurchaseCommon Stock	454,545	$11.00	$4,999,995.00	Disclosure SEC source: 0001209191-23-054904 · doc4.xml · nonDerivative · entry 3 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Longitude Venture Partners IV, L.P. Disclosed balance after: 2,567,100 F2 · ownership.nature: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
November 07, 2023 Filed Nov 10, 2023 01:32 UTC	Lexeo Therapeutics, Inc. LXEO · Entity 5687	ConversionCommon Stock	319,126	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-054904 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Longitude Venture Partners IV, L.P. Disclosed balance after: 2,112,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
November 07, 2023 Filed Nov 10, 2023 01:32 UTC	Lexeo Therapeutics, Inc. LXEO · Entity 5687	ConversionCommon Stock	1,793,429	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-054904 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Longitude Venture Partners IV, L.P. Disclosed balance after: 1,793,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
February 06, 2023 Filed Feb 8, 2023 19:40 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	1,714,285	$7.00	$11,999,995.00	Disclosure SEC source: 0000899243-23-004349 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,714,285 F1 · ownership.nature: These shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
February 10, 2022 Filed Apr 5, 2022 11:24 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	333,333	$15.00	$4,999,995.00	Disclosure SEC source: 0000899243-22-013598 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,429,927 F1 · ownership.nature: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Mr. Enright, a managing member of LCP IV, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Read SEC document
May 18, 2021 Filed May 19, 2021 00:20 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	ConversionSeries C Preferred Stock · Derivative	2,187,504	$0.00	$0.00	Disclosure SEC source: 0001209191-21-033816 · doc4.xml · derivative · entry 3 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 2,187,504 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date. F1 · derivative.exercise_date: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Mr. Enright, a managing member of LCP IV, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Read SEC document
May 18, 2021 Filed May 19, 2021 00:20 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	909,090	$11.00	$9,999,990.00	Disclosure SEC source: 0001209191-21-033816 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,096,594 F2 · ownership.nature: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Mr. Enright, a managing member of LCP IV, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Read SEC document
May 18, 2021 Filed May 19, 2021 00:20 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	ConversionClass A Common Stock	2,187,504	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-033816 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,187,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Mr. Enright, a managing member of LCP IV, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Read SEC document
April 14, 2021 Filed Apr 16, 2021 01:00 UTC	Eargo, Inc. EAR · Entity 94112	OtherCommon Stock	5,012	$0.00	$0.00	Disclosure SEC source: 0000899243-21-016024 · doc4.xml · nonDerivative · entry 2 Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,012 F4 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP4 to its members. F5 · ownership.nature: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document
April 14, 2021 Filed Apr 16, 2021 01:00 UTC	Eargo, Inc. EAR · Entity 94112	OtherCommon Stock	1,000,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-016024 · doc4.xml · nonDerivative · entry 1 Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,918,691 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners IV, L.P. ("LVP4") to its general and limited partners, pursuant to a Rule 10b5-1 trading plan. F2 · ownership.direct: These shares are held directly by LVP4. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of LVP4 and may be deemed to have voting, investment and dispositive power over the shares held by LVP4. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVP4. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by LVP4 and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. F3 · ownership.direct: (Continued from footnote 2) Juliet Tammenoms Bakker, a managing member of LCP4, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Read SEC document
October 20, 2020 Filed Oct 23, 2020 00:24 UTC	Eargo, Inc. EAR · Entity 94112	ConversionSeries E Preferred Stock · Derivative	3,685,358	$0.00	$0.00	Disclosure SEC source: 0000899243-20-029109 · doc4.xml · derivative · entry 3 Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,685,358 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series E Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The Series E Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series E Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.direct: These shares are are held directly by the Reporting Person. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of the Reporting Person and may be deemed to have voting, investment and dispositive power over the shares held by the Reporting Person. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by the Reporting Person. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by the Reporting Person and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.. Read SEC document
October 20, 2020 Filed Oct 23, 2020 00:24 UTC	Eargo, Inc. EAR · Entity 94112	PurchaseCommon Stock	233,333	$18.00	$4,199,994.00	Disclosure SEC source: 0000899243-20-029109 · doc4.xml · nonDerivative · entry 2 Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,918,691 F2 · ownership.direct: These shares are are held directly by the Reporting Person. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of the Reporting Person and may be deemed to have voting, investment and dispositive power over the shares held by the Reporting Person. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by the Reporting Person. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by the Reporting Person and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.. Read SEC document
October 20, 2020 Filed Oct 23, 2020 00:24 UTC	Eargo, Inc. EAR · Entity 94112	ConversionCommon Stock	3,685,358	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-029109 · doc4.xml · nonDerivative · entry 1 Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,685,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series E Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.direct: These shares are are held directly by the Reporting Person. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of the Reporting Person and may be deemed to have voting, investment and dispositive power over the shares held by the Reporting Person. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by the Reporting Person. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by the Reporting Person and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.